Related Experiment Videos
Safety and immunogenicity of a diphtheria-tetanus-pertussis vaccine containing an acellular pertussis component
Insights
This study found that a new diphtheria-tetanus-pertussis (DTP) vaccine was safe and effective in children aged 4-6 years. The DTP vaccine demonstrated good immunogenicity, with most children showing enhanced antibody titers after vaccination.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- The diphtheria-tetanus-pertussis (DTP) vaccine is crucial for childhood immunization.
- Evaluating new vaccine formulations is essential for improving public health outcomes.
Purpose of the Study:
- To assess the safety and immunogenicity of a novel DTP vaccine with an acellular pertussis component.
- To evaluate the vaccine's efficacy in children aged 4 to 6 years who had previously completed their primary DTP series and received a booster.
Main Methods:
- An open-label study was conducted involving 31 healthy children aged 4-6 years.
- Participants received a single dose of the experimental DTP vaccine.
- Safety was monitored through adverse event reporting, and immunogenicity was assessed via paired antibody assays for diphtheria, tetanus, and pertussis.
Main Results:
- The vaccine was generally well-tolerated, with two subjects experiencing fever and eleven reporting mild local reactions.
- One subject developed a sterile abscess.
- Antibody titers were enhanced in a high percentage of subjects: 19 of 21 for pertussis, 20 of 21 for diphtheria, and 19 of 21 for tetanus.
Conclusions:
- The experimental DTP vaccine containing an acellular pertussis component demonstrated a favorable safety profile in the studied population.
- The vaccine proved to be immunogenic, effectively enhancing antibody titers against diphtheria, tetanus, and pertussis.
- Despite the small sample size, the findings suggest the vaccine is safe and effective for children in this age group.
Abstract:
In an open-label study, we evaluated the safety and immunogenicity of a diphtheria-tetanus-pertussis (DTP) vaccine containing an acellular pertussis component. Thirty-one normal, healthy children 4 to 6 years old received a single dose. All subjects had received their primary DTP series and DTP booster at age 18 months. All but three of the subjects were followed up for one month. Two subjects developed fever (100 F [37.8 C]) during the 24 hours after dosing. Eleven subjects had mild local reactions reported by parents at the 24-hour visit. One subject had a small "sterile abscess." Paired antibody assays revealed enhancement of titers in 19 of 21 for pertussis, 20 of 21 for diphtheria, and 19 of 21 for tetanus. Although the sample is small, the experimental vaccine appears to have been safe and effective in the subjects studied.